key: cord-0811540-j0lwri46
authors: Treger, Sharon; Shiloh, Sivan R.; Ben-Valid, Tal; Ganor Paz, Yael; Sharvit, Merav; Bryk, Gabriel; Brosh-Nissimov, Tal; Barzilay, Eran
title: Trans-Placental Transfer of SARS-Cov-2 Antibodies in recovered and BNT162b2-vaccinated patients
date: 2021-12-01
journal: Am J Obstet Gynecol
DOI: 10.1016/j.ajog.2021.11.1365
sha: 62293c604bb84ded540208f1cf06fd40f31f965b
doc_id: 811540
cord_uid: j0lwri46

nan

limited, including only three studies concerning late third trimester vaccination. [2] [3] [4] The objective 23 of this study was to assess the trans-placental transfer of anti-SARS-CoV-2 antibodies in women 24 vaccinated with the BNT162b2 vaccine during the second and third trimester.

Study design: 26 A total of 40 parturients with singleton term pregnancies were recruited. Samples were collected 27 from maternal and cord blood. Samples were analyzed for Anti-Nucleocapsid (anti-N) and anti-28 Spike (anti-S) antibodies in both maternal and neonatal samples. The study was approved by the 29 local IRB (approval number 0055-21-AAA) and written informed consent was obtained from all 30 participants.

Of the 40 women recruited, 28 were vaccinated with two doses of BNT162b2 vaccine and 12 33 were COVID-19-convalescents (Supplemental Table 1 ). Median interval between COVID-19 34 diagnosis and delivery in the recovered group was 20.6 weeks (IQR 17.6-36.9 weeks), while 35 median interval between second vaccine and delivery in the vaccinated group was 11.1 weeks 36 (IQR 9.3-15 weeks). Two women in the vaccinated group were Anti-N-positive, suggesting past 37 unknown infection (Supplemental Table 2 ).

Overall, maternal anti-S antibody levels were significantly higher in the vaccinated group 39 compared to the recovered group (145, vs. 41, IQR 19 -95 AU/mL, respectively, maternal levels in both groups (185, p<0 .001). There was no 43 significant difference in neonatal/maternal anti-S ratio between the groups (Table 1) .

There was a significant correlation between maternal and neonatal anti-S antibody levels (r 45 0.922, p<0.001). However, there was no correlation between maternal anti-S levels and 46 neonatal/maternal anti-S ratio, nor between maternal anti-S levels and the interval to delivery.

Moreover, the lack of correlation between maternal anti-S levels and the interval to delivery was 48 also apparent when assessing the vaccinated and the recovered groups separately (Supplemental 49   Table 3 ).

Regarding factors that may affect trans-placental anti-S antibody transfer, using a linear 51 regression model (Figure 1 ), we found that only birthweight had a significant positive impact on 52 neonatal/maternal anti-S ratio (Beta-coefficient 0.509, 95%CI 0.032-0.986, p=0.037).

This study is the first to assess the maternal-neonatal transfer of SARS-COV-2 antibodies in 55 women that were vaccinated during the second trimester. Previously published studies, assessed 56 transfer of anti-SARS-CoV-2 antibodies in women that were vaccinated in the late third 57 trimester 2-4 and in some cases without completing the vaccination course (i.e. one week 58 following the second dose). 2 The fact that vaccinations were given close to delivery may explain 59 the low neonatal-maternal antibody ratio of found in all these studies. In contrast, our study 60 found a high neonatal-maternal antibody ratio, similar to that found in other vaccines. was maintained. We did not find an association between vaccination-delivery or infection-64 delivery interval and antibody levels. This can be explained by the relatively short time frame of our study and the fact that the study's population was comprised of young, healthy women.

Birthweight was found to affect trans-placental antibody transfer. This is in accordance with 67 previous data showing a correlation between birthweight and antibody transfer. 5 We could not 68 assess the correlation between gestational age and antibody transfer since all cases in this study 69 were term deliveries.

Our study has a few limitations. The small sample size may prevent us from detecting a time-71 depended decrease in antibody levels or other factors that may affect trans-placental antibody 72 transfer in addition to birthweight. Differences between the vaccinated and recovered groups 73 may be a source of bias. Use of multivariate analyses reduces that risk, however, the risk of 74 residual bias cannot be eliminated. We have no data regarding vaccines other than BNT162b2, 75 which was used exclusively in Israel. Lastly, waning of antibody titers in the neonates is yet to 76 be determined.

In conclusion, neonatal SARS-CoV-2 antibody levels were higher than maternal levels in both 78 vaccinated and recovered patients. Antibody levels in newborns of vaccinated mothers were 3.4 79 fold higher than in newborns of recovered mothers. Since the protection afforded to neonates is 

Hospitalization Rates and Characteristics of Children 86